Trial Outcomes & Findings for A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity (NCT NCT00546455)
NCT ID: NCT00546455
Last Updated: 2021-02-10
Results Overview
This study was terminated due to expired drug with possibility of re-starting in the future. For this reason the randomization code has not been broken and the data has not been analyzed and there is no way to report the outcome measures.
SUSPENDED
PHASE2
21 participants
30 days
2021-02-10
Participant Flow
This study was terminated due to expired drug with possibility of re-starting in the future. For this reason the randomization code has not been broken and the data has not been analyzed and there is no way to report the participant flow.
Participant milestones
| Measure |
A- Fenretinide
Subjects in this cohort will be given Fenretinide
Fenretinide: 200 mg/day
|
B-Placebo
Subjects in this cohort will be given placebo.
Placebo: 2 capsules/day
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 30 daysPopulation: This study was terminated due to expired drug with possibility of re-starting in the future. For this reason the randomization code has not been broken and the data has not been analyzed and there is no way to report the outcome measures.
This study was terminated due to expired drug with possibility of re-starting in the future. For this reason the randomization code has not been broken and the data has not been analyzed and there is no way to report the outcome measures.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 30 daysPopulation: This study was terminated due to expired drug with possibility of re-starting in the future. For this reason the randomization code has not been broken and the data has not been analyzed and there is no way to report the outcome measures.
This study was terminated due to expired drug with possibility of re-starting in the future. For this reason the randomization code has not been broken and the data has not been analyzed and there is no way to report the outcome measures.
Outcome measures
Outcome data not reported
Adverse Events
A- Fenretinide
B-Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place